Aktienanalyse zu Quest Diagnostics Inc (DGX)DGXQuest Diagnostics Inc

Quest Diagnostics Incorporated is a provider of diagnostic information services. It provides diagnostic insights from the results of its laboratory testing to empower people, physicians, and organizations to take action to improve health outcomes. It operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and its connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. Its other customers include health plans, employers, emerging retail healthcare providers, government agencies, and others. Its services are provided under the Quest Diagnostics brand and under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

Quest Diagnostics Inc is currently priced at $230.97, which is below the average analyst price target of $250 to $260, suggesting potential upside. However, the stock has an RSI of 44.641, indicating it is nearing oversold territory, but not yet a strong buy signal. The recent announcement of a 15% cut in lab reimbursement rates by CMS poses a significant risk, potentially impacting about 11% of Quest's revenue, which could lead to a decrease in revenue by approximately 1.65% annually. Given these factors, it may be prudent to hold rather than buy at this moment, awaiting clearer signals from upcoming earnings on October 22, 2026.

20 analysts cover DGX: 5 rate it Buy, 14 Hold and 1 Sell. The average price target is 203.33.